Feasible usage of ABO incompatible grafts in living donor liver transplantation
Identifieur interne : 000453 ( Pmc/Curation ); précédent : 000452; suivant : 000454Feasible usage of ABO incompatible grafts in living donor liver transplantation
Auteurs : Toru Ikegami ; Tomoharu Yoshizumi ; Yuji Soejima ; Hideaki Uchiyama ; Ken Shirabe ; Yoshihiko MaeharaSource :
- Hepatobiliary Surgery and Nutrition [ 2304-3881 ] ; 2016.
Abstract
The use of ABO incompatible (ABOi) graft in living donor liver transplantation (LDLT) has not been an established procedure worldwide.
Four hundred and eight adult LDLTs, using ABOi (n=19) and non-ABOi (n=389) grafts, were performed as a single center experience.
In ABOi-LDLT group (n=19), median isoagglutinin titer before plasma exchange (PE) at LDLT and after LDLT (max) was ×256, ×32 and ×32, respectively. Rituximab was given at 21.8±6.1 days before LDLT and PE was performed 3.7±1.6 times. Although ABOi-LDLTs had increased rate of splenectomy (89.4%
ABOi-LDLT could be safely performed, especially under rituximab-based protocol.
Url:
DOI: 10.3978/j.issn.2304-3881.2015.06.02
PubMed: 27115002
PubMed Central: 4824747
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000453
Links to Exploration step
PMC:4824747Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Feasible usage of ABO incompatible grafts in living donor liver transplantation</title><author><name sortKey="Ikegami, Toru" sort="Ikegami, Toru" uniqKey="Ikegami T" first="Toru" last="Ikegami">Toru Ikegami</name></author><author><name sortKey="Yoshizumi, Tomoharu" sort="Yoshizumi, Tomoharu" uniqKey="Yoshizumi T" first="Tomoharu" last="Yoshizumi">Tomoharu Yoshizumi</name></author><author><name sortKey="Soejima, Yuji" sort="Soejima, Yuji" uniqKey="Soejima Y" first="Yuji" last="Soejima">Yuji Soejima</name></author><author><name sortKey="Uchiyama, Hideaki" sort="Uchiyama, Hideaki" uniqKey="Uchiyama H" first="Hideaki" last="Uchiyama">Hideaki Uchiyama</name></author><author><name sortKey="Shirabe, Ken" sort="Shirabe, Ken" uniqKey="Shirabe K" first="Ken" last="Shirabe">Ken Shirabe</name></author><author><name sortKey="Maehara, Yoshihiko" sort="Maehara, Yoshihiko" uniqKey="Maehara Y" first="Yoshihiko" last="Maehara">Yoshihiko Maehara</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27115002</idno><idno type="pmc">4824747</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824747</idno><idno type="RBID">PMC:4824747</idno><idno type="doi">10.3978/j.issn.2304-3881.2015.06.02</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000453</idno><idno type="wicri:Area/Pmc/Curation">000453</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Feasible usage of ABO incompatible grafts in living donor liver transplantation</title><author><name sortKey="Ikegami, Toru" sort="Ikegami, Toru" uniqKey="Ikegami T" first="Toru" last="Ikegami">Toru Ikegami</name></author><author><name sortKey="Yoshizumi, Tomoharu" sort="Yoshizumi, Tomoharu" uniqKey="Yoshizumi T" first="Tomoharu" last="Yoshizumi">Tomoharu Yoshizumi</name></author><author><name sortKey="Soejima, Yuji" sort="Soejima, Yuji" uniqKey="Soejima Y" first="Yuji" last="Soejima">Yuji Soejima</name></author><author><name sortKey="Uchiyama, Hideaki" sort="Uchiyama, Hideaki" uniqKey="Uchiyama H" first="Hideaki" last="Uchiyama">Hideaki Uchiyama</name></author><author><name sortKey="Shirabe, Ken" sort="Shirabe, Ken" uniqKey="Shirabe K" first="Ken" last="Shirabe">Ken Shirabe</name></author><author><name sortKey="Maehara, Yoshihiko" sort="Maehara, Yoshihiko" uniqKey="Maehara Y" first="Yoshihiko" last="Maehara">Yoshihiko Maehara</name></author></analytic><series><title level="j">Hepatobiliary Surgery and Nutrition</title><idno type="ISSN">2304-3881</idno><idno type="eISSN">2304-389X</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>The use of ABO incompatible (ABOi) graft in living donor liver transplantation (LDLT) has not been an established procedure worldwide.</p></sec><sec><title>Methods</title><p>Four hundred and eight adult LDLTs, using ABOi (n=19) and non-ABOi (n=389) grafts, were performed as a single center experience.</p></sec><sec><title>Results</title><p>In ABOi-LDLT group (n=19), median isoagglutinin titer before plasma exchange (PE) at LDLT and after LDLT (max) was ×256, ×32 and ×32, respectively. Rituximab was given at 21.8±6.1 days before LDLT and PE was performed 3.7±1.6 times. Although ABOi-LDLTs had increased rate of splenectomy (89.4% <italic>vs.</italic> 44.7%, P<0.001) and lower portal venous pressure (PVP) at the end of surgery (13.8±1.1 <italic>vs.</italic> 16.9±0.2 mmHg, P=0.003), other operative factors including graft ischemic time, operative time and blood loss were not different between the groups. Although ABOi-LDLTs had increased incidence of cytomegalovirus infection (52.6% <italic>vs.</italic> 22.9%, P=0.007), other post-transplant complications including bacterial sepsis and acute rejection were not different between the groups. The 5-year graft survival rate was 87.9% in ABOi-LDLTs and 80.3% in non-ABOi-LDLTs (P=0.373).</p></sec><sec><title>Conclusions</title><p>ABOi-LDLT could be safely performed, especially under rituximab-based protocol.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Hepatobiliary Surg Nutr</journal-id><journal-id journal-id-type="iso-abbrev">Hepatobiliary Surg Nutr</journal-id><journal-id journal-id-type="publisher-id">HBSN</journal-id><journal-title-group><journal-title>Hepatobiliary Surgery and Nutrition</journal-title></journal-title-group><issn pub-type="ppub">2304-3881</issn><issn pub-type="epub">2304-389X</issn><publisher><publisher-name>AME Publishing Company</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27115002</article-id><article-id pub-id-type="pmc">4824747</article-id><article-id pub-id-type="publisher-id">hbsn-05-02-091</article-id><article-id pub-id-type="doi">10.3978/j.issn.2304-3881.2015.06.02</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Feasible usage of ABO incompatible grafts in living donor liver transplantation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ikegami</surname><given-names>Toru</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yoshizumi</surname><given-names>Tomoharu</given-names></name></contrib><contrib contrib-type="author"><name><surname>Soejima</surname><given-names>Yuji</given-names></name></contrib><contrib contrib-type="author"><name><surname>Uchiyama</surname><given-names>Hideaki</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shirabe</surname><given-names>Ken</given-names></name></contrib><contrib contrib-type="author"><name><surname>Maehara</surname><given-names>Yoshihiko</given-names></name></contrib><aff id="aff1">Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582,<country>Japan</country></aff></contrib-group><author-notes><fn id="afn1"><p><italic>Contributions:</italic> (I) Conception and design: T Ikegami, T Yoshizumi; (II) Administrative support: K Shirabe, Y Maehara; (III) Provision of study materials or patients: Y Soejima; (IV) Collection and assembly of data: H Uchiyama, K Shirabe; (V) Data analysis and interpretation: T Ikegami, H Uchiyama; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.</p></fn><corresp id="cor1"><italic>Correspondence to:</italic> Toru Ikegami, MD. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. Email: <email xlink:href="tikesurg@surg2.med.kyushu-u.ac.jp">tikesurg@surg2.med.kyushu-u.ac.jp</email>.</corresp></author-notes><pub-date pub-type="epub-ppub"><month>4</month><year>2016</year></pub-date><pmc-comment>Fake ppub date generated by PMC from publisher
pub-date/@pub-type='epub-ppub' </pmc-comment>
<pub-date pub-type="ppub"><month>4</month><year>2016</year></pub-date><volume>5</volume><issue>2</issue><fpage>91</fpage><lpage>97</lpage><history><date date-type="received"><day>26</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>2016 Hepatobiliary Surgery and Nutrition. All rights reserved.Hepatobiliary Surgery and Nutrition. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Hepatobiliary Surgery and Nutrition.</copyright-holder></permissions><abstract><sec><title>Background</title><p>The use of ABO incompatible (ABOi) graft in living donor liver transplantation (LDLT) has not been an established procedure worldwide.</p></sec><sec><title>Methods</title><p>Four hundred and eight adult LDLTs, using ABOi (n=19) and non-ABOi (n=389) grafts, were performed as a single center experience.</p></sec><sec><title>Results</title><p>In ABOi-LDLT group (n=19), median isoagglutinin titer before plasma exchange (PE) at LDLT and after LDLT (max) was ×256, ×32 and ×32, respectively. Rituximab was given at 21.8±6.1 days before LDLT and PE was performed 3.7±1.6 times. Although ABOi-LDLTs had increased rate of splenectomy (89.4% <italic>vs.</italic> 44.7%, P<0.001) and lower portal venous pressure (PVP) at the end of surgery (13.8±1.1 <italic>vs.</italic> 16.9±0.2 mmHg, P=0.003), other operative factors including graft ischemic time, operative time and blood loss were not different between the groups. Although ABOi-LDLTs had increased incidence of cytomegalovirus infection (52.6% <italic>vs.</italic> 22.9%, P=0.007), other post-transplant complications including bacterial sepsis and acute rejection were not different between the groups. The 5-year graft survival rate was 87.9% in ABOi-LDLTs and 80.3% in non-ABOi-LDLTs (P=0.373).</p></sec><sec><title>Conclusions</title><p>ABOi-LDLT could be safely performed, especially under rituximab-based protocol.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>ABO incompatible (ABOi)</kwd><kwd>living donor liver transplantation (LDLT)</kwd><kwd>rituximab</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/HapticV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000453 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000453 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Ticri/CIDE
|area= HapticV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:4824747
|texte= Feasible usage of ABO incompatible grafts in living donor liver transplantation
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:27115002" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a HapticV1
| This area was generated with Dilib version V0.6.23. |  |